ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

KRAS G12C Inhibitor HS-10370

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Hansoh Pharmaceutical Group.

Furthest: phase 3, since Sep 11, 20262 company-led studies, 1 open or runningNext primary completion: May 31, 2030 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hansoh Pharmaceutical Group21 open or runningphase 3since Sep 11, 2026May 5, 2022May 31, 2030phase 3 · NCT07822542

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 5, 2022First study: phase 2 study in Advanced Solid TumorFirst studyNCT05367778 · 176 enrolled · China
  2. Sep 11, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungPhase 3 reachedNCT07822542 · 448 planned

Ahead

  1. May 31, 2030Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07822542

TargetBeta

KRAS →read by rule
“An orally bioavailable small molecule inhibitor of the oncogenic KRAS substitution mutation, G12C, ”NCIt, by rule

Other programs on KRAS

ProgramCompanyFurthest phaseStudies
sotorasibruleAmgenphase 328
adagrasibruleBristol-Myers Squibbphase 316
olomorasibEli Lillyphase 316
divarasibHoffmann-La Rochephase 313
KRAS G12D Inhibitor VS-7375ruleGenfleet Therapeutics (Shanghai)phase 312
glecirasibruleAllist Pharmaceuticalsphase 312
calderasibMerckphase 312
daraxonrasibruleRevolution Medicinesphase 310
garsorasibruleInventisBiophase 38
KRAS G12D Inhibitor HRS-4642Jiangsu HengRui Medicinephase 37
zoldonrasibruleRevolution Medicinesphase 36
HRS-7058Jiangsu HengRui Medicinephase 36

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07822542Carcinoma, Non-Small-Cell Lung3Not yet recruitingMay 31, 2030448
NCT05367778Advanced Solid Tumor · China2UNKNOWNApr 30, 2025176

How it is read

Names in the registry

  • “HS-10370”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.